Nephro Care India SME IPO
Company Overview
Incorporated in 2014, Nephro Care India Limited is a comprehensive treatment center located in Kolkata, specializing in renal insufficiency treatment and offering a wide range of clinical and lifestyle solutions. The hospital is supported by expert doctors, experienced paramedical professionals, and a skilled management team.
Services Provided
Nephro Care India serves approximately 900 Chronic Kidney Disease patients each month. The hospital has:
5 permanent doctors
10 visiting consultants
70 experienced paramedical professionals
These services are delivered from its main clinic in Salt Lake, covering an area of 5,352 square feet, and three satellite clinics in Salt Lake (HB 113) and Chandannagar, West Bengal.
Current Services Offered:
Outpatient Services: Nephrology, Diabetology, Cardiology, Ophthalmology, and Neurology
In-house Pharmacy, Pathology & Home Care Services
Promoter Details
Promoter: Dr. Pratim Sengupta
Pre-Issue Share Holding: 85.02%
Post-Issue Share Holding: 61.39%
Objects of the Issue
The funds raised from the IPO will be utilized for:
Setting up Multi-Speciality Hospitals
General Corporate Expenses
Nephro Care India: Key IPO Details
IPO Dates: 28 June to 2 July 2024
Price Band: ₹85 to ₹90 per share
Lot Size: 1600 shares
Amount Per Lot: ₹1,44,000
Total Issue Size: ₹41.26 Crores
Retail Quota: 31.52%
GMP: +120% (For Informational Purposes Only)
DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matters published here are purely for educational and information purposes only and under no circumstances should be used for making investment decisions. Readers must consult a qualified financial advisor before making any actual investment decisions, based on the information published here. Any reader making decisions based on any information published here does so entirely at their own risk. Investors should bear in mind that any investment in the stock market is subject to unpredictable market-related risks. The author has no plans to invest in this offer and also the author does not recommend investing in any offer published on this website.